Is Sanofi-Aventis After Bristol-Myers?

Word is the two major pharmaceuticals may soon merge and become the world's largest drugmaker ahead of some best-selling drugs coming off patent

Speculation is mounting that the long-rumored merger between Franco-German drugmaker Sanofi-Aventis and New York-based Bristol-Myers Squibb may soon be reality. If true, the deal will enable Sanofi to vault past Pfizer (PFE) and Britain's GlaxoSmithKline (GSK) to become the world's largest drugmaker, with combined annual revenues of nearly $55 billion. Neither company is commenting. But a recent report in French financial newsletter La Lettre de l'Expansion claims the two companies have already signed a pre-merger agreement.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.